<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02737189</url>
  </required_header>
  <id_info>
    <org_study_id>Xuanwu201601</org_study_id>
    <nct_id>NCT02737189</nct_id>
  </id_info>
  <brief_title>Basilar Artery Occlusion Chinese Endovascular Trial</brief_title>
  <official_title>Randomized Trial of Revascularization With Solitaire Stentriever Versus Best Medical Therapy in the Treatment of Acute Ischemic Stroke Due to Basilar Artery Occlusion Presenting Within 6-24 Hours of Symptom Onset</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhangzhou Municipal Hospital of Fujian Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First People's Hospital of Changzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baotou Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The 101st Hospital of Chinese People's Liberation Army</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Linyi People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongshan People's Hospital, Guangdong, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PLA 264 Hospital, Taiyuan, Shanxi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanjing First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin TEDA Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaocheng Third People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Luoyang Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Subei People's Hospital of Jiangsu Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PLA 148 Hospital, Zibo, Shandong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebei General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengli Oilfield Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The 306 Hospital of People's Liberation Army</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Bao'an District People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University Binhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Military General Hospital of Beijing, PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Shanxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Luhe Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nantong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital Of Guizhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanning Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chongqing Three Gorges Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endovascular treatment of acute ischemic stroke has shown strong benefit in several
      prospective randomized trials in the anterior circulation and endovascular therapy for
      basilar artery occlusion has shown promising results in several single-arm studies. This has
      led to a broad adoption of these techniques which are now considered standard of care in many
      institutions despite the lack of adequate evidence to prove their benefit. Indeed, the rates
      of symptomatic intracerebral hemorrhage in these studies have consistently been around 5%
      which raises the question as to whether patients could actually be harmed as opposed to
      helped by these procedures. This is a prospective, multi-center, randomized, controlled,
      open, blinded-endpoint trial, with the aim to evaluate the hypothesis that mechanical
      embolectomy with the Solitaire device is superior to medical management alone in achieving
      better outcomes in subjects presenting with an acute ischemic stroke caused by occlusion of
      the basilar artery within 6-24 hours from symptom onset.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objective: To evaluate the hypothesis that mechanical embolectomy with the Solitaire
      device is superior to medical management alone in achieving meaningful outcomes (better than
      death or equivalent) defined as modified Rankin score (mRS) 0-4 at 90 days in subjects
      presenting with ischemic stroke due to basilar artery occlusion up to 24 hours from symptom
      onset.

      Subject Population: Subjects presenting with acute ischemic stroke within 6-24 hours from
      symptom onset/last seen well and whose strokes are attributable to an occlusion of the
      basilar artery. Subjects are either ineligible for IV alteplase or have received IV alteplase
      therapy without recanalization. The randomization employs a 1:1 ratio of mechanical
      embolectomy with Solitaire stentriever in conjunction with manual aspiration versus medical
      management alone. Randomization will be done under a stratification process using age,
      baseline National Institute of Health Stroke Scale (NIHSS) and therapeutic window. For the
      primary endpoint, subjects will be followed for 90 days post-randomization.Sample size is
      projected to be 318 patients.

      Care providers: Vascular neurologists and trained interventional neuroradiologists or
      neurologists in certified comprehensive stroke centers that treat more than 500 acute stroke
      patients and perform more than 30 acute mechanical thrombectomies every year will treat
      patients. Neurointerventionalists have to have previously performed at least 10
      thrombectomies with Solitaire device in acute ischemic stroke patients.

      Interventions: Patients in both arms will be admitted at acute stroke units (or Intensive
      Care Unit if needed) and treated following the Chinese Guidelines for the Early Management of
      Patients With Acute Ischemic Stroke. Concomitant medications and non-pharmacological
      therapies will be recorded. If a decision of stopping support life measures is adopted, this
      will be recorded in the Case Report Form (CRF).A maximum of six attempts to retrieve the
      thrombus in a single vessel can be made with any Solitaire device or aspiration. In case an
      atherosclerotic lesion is found underlying the occlusive lesion angioplasty/stenting through
      detachment of the Solitaire device will be allowed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients achieving meaningful outcomes</measure>
    <time_frame>90 days</time_frame>
    <description>The primary objective of this study is to evaluate the hypothesis that mechanical embolectomy with the Solitaire device is superior to medical management alone in achieving meaningful outcomes (better than death or equivalent) (mRS ≤ 4) at 90 days in subjects presenting with an acute ischemic stroke caused by occlusion of the basilar artery within 6-24 hours from symptom onset.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary endpoint at one year</measure>
    <time_frame>1 year</time_frame>
    <description>Proportion of patients achieving meaningful outcomes defined as mRS 0-4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving favorable outcomes defined as mRS 0-2</measure>
    <time_frame>90 days and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dramatic early favorable response</measure>
    <time_frame>90 days</time_frame>
    <description>Dramatic early favorable response as determined by an National Institute of Health stroke scale (NIHSS) of 0-2 or NIHSS improvement ≥ 8 points at 24 (-2/+12 hours) hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Final infarct volume</measure>
    <time_frame>24 hours (-2/+12 hours)</time_frame>
    <description>Infarct volume evaluated on Computed Tomography (CT) or Magnetic Resonance (MR) at 24 hours (-2/+12 hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vessel recanalization with Arterial Occlusive Lesion (AOL) grades</measure>
    <time_frame>24 hours (-2/+12 hours)</time_frame>
    <description>Vessel recanalization evaluated by CT angiography (CTA) or MR Angiography (MRA) at 24 hours (-2/+12 hours) in both treatment groups as TIMI grades classified by a central Core-Lab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Score (mRS)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life analysis</measure>
    <time_frame>3 month, 6 months and 1 year</time_frame>
    <description>Quality of life analysis as measured by EuroQol/EQ5D and SF-36 at 3 month, 6 months and 1 year, between interventional therapy vs medical therapy alone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>at 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracranial hemorrhage (SICH)</measure>
    <time_frame>24 (-2/+12) hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognition Test (MOCA)</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">318</enrollment>
  <condition>Basilar Artery Occlusion</condition>
  <condition>Ischemic Stroke</condition>
  <condition>Cerebrovascular Disorders</condition>
  <arm_group>
    <arm_group_label>Endovascular Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration
Best Medical Treatment and maximum supportive care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mechanical embolectomy</intervention_name>
    <description>Mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration</description>
    <arm_group_label>Endovascular Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medical Treatment</intervention_name>
    <description>Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment</description>
    <arm_group_label>Endovascular Arm</arm_group_label>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acute ischemic stroke due to basilar artery occlusion within 6-24 hours from symptom
             onset，where patient is ineligible for IV thrombolytic treatment or the treatment is
             contraindicated (e.g., subject presents beyond recommended time from symptom onset),
             or where patient has received IV thrombolytic therapy without recanalization.

          2. Occlusion of the basilar artery (TIMI 0-1) as evidenced by CTA, MRA or angiogram.

          3. Age ≥18 and ≤80 years.

          4. Baseline NIHSS score obtained prior to randomization ≥10.

          5. No significant pre-stroke disability (mRS ≤1).

          6. Subject treatable within 24 hours from symptoms onset or time last seen at baseline
             (i.e., subjects who have stroke symptoms upon awakening will be considered to have
             their &quot;onset&quot; at beginning of sleep; subjects who are found with new stroke symptoms
             and are unable to communicate the actual time of symptoms onset will be considered to
             have their &quot;onset&quot; at the last time they were seen well). Treatment initiation is
             defined as groin or other access site puncture. Symptoms onset include vertigo,
             diplopia, midline ataxia, visual loss, sensory or motor deficits.

          7. Anticipated life expectancy of at least 1 year.

          8. Informed consent obtained from Subject or acceptable Subject Surrogate.

        Exclusion Criteria:

          1. Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant
             therapy with International Normalized Ratio (INR) ＞3.0

          2. Baseline platelet count ＜50000/µL

          3. Baseline blood glucose of ＜50mg/dL or ＞400mg/dL.

          4. Severe, sustained hypertension (systolic blood pressure ＞220 mm Hg or diastolic blood
             pressure ＞110 mm Hg) Note: If the blood pressure can be successfully reduced and
             maintained at the acceptable level using local treatment guidelines recommended
             medication (including iv antihypertensive drips), the patient can be enrolled.

          5. Intubated patients for transfer could be randomized only in case an NIHSS is obtained
             by a neurologist prior transportation.

          6. Seizures at stroke onset which would preclude obtaining a baseline NIHSS.

          7. History of life threatening allergy (more than rash) to contrast medium.

          8. Subjects who have received iv recombinant tissue plasminogen activator
             （rt-PA）treatment beyond 4.5 hours from the beginning of the symptoms.

          9. Patients with acute stroke within the first 48 hours after percutaneous cardiac,
             cerebrovascular interventions and major surgery (beyond 48h they should be randomized
             or excluded if poor medical conditions)

         10. Renal insufficiency with creatinine ≥3 mg/dL.

         11. Woman of childbearing potential who is known to be pregnant or lactating or who has a
             positive pregnancy test on admission.

         12. Subject participating in a study involving an investigational drug or device that
             would impact this study.

         13. Cerebral vasculitis.

         14. Patients with a pre-existing neurological or psychiatric disease that would confound
             the neurological or functional evaluations, mRS score at baseline must be ≤1. This
             excludes patients who are severely demented, require constant assistance in a nursing
             home type setting or who live at home but are not fully independent in activities of
             daily living (toileting, dressing, eating, cooking and preparing meals, etc.)

         15. Unlikely to be available for 1 year follow-up (e.g. no fixed home address, visitor
             from overseas).

         16. Posterior circulation ASPECTS ＜6 and Pons-midbrain-index of ≥3.

         17. CT or MR evidence of hemorrhage (the presence of microbleeds is allowed).

         18. Complete cerebellar infarct on CT or MRI with significant mass effect and compression
             of the 4-th ventricle.

         19. Complete thalamic infarction on CT or MRI.

         20. Evidence of vertebral occlusion, high grade stenosis or arterial dissection in the
             extracranial or petrous segment of the vessel that cannot be treated or will prevent
             access to the intracranial clot or excessive tortuosity of cervical vessels precluding
             device delivery/deployment.

         21. Subjects with occlusions in multiple vascular territories ( anterior circulation and
             posterior circulation).

         22. Evidence of intracranial tumor (except small meningioma).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xunming Ji, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuanwu Hospital, Beijing</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tudor G Jovin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburg Medical Center Stroke</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chuanhui Li, MD</last_name>
    <phone>15210439828</phone>
    <email>lichuanhui365@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baotou Central Hospital</name>
      <address>
        <city>Baotou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changchun Jiang</last_name>
    </contact>
    <investigator>
      <last_name>Changchun Jiang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Luhe Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaokun Geng</last_name>
    </contact>
    <investigator>
      <last_name>Xiaokun Geng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhongrong Miao</last_name>
    </contact>
    <investigator>
      <last_name>Zhongrong Miao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The 306 Hospital of People's Liberation Army</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yiling Cai</last_name>
    </contact>
    <investigator>
      <last_name>Yiling Cai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Military General Hospital of Beijing, PLA</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qiang Zhang</last_name>
    </contact>
    <investigator>
      <last_name>Qiang Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xuanwu Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chuanhui Li</last_name>
    </contact>
    <contact_backup>
      <last_name>Ming Ren</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jian Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chuanhui Li</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Changzhou</name>
      <address>
        <city>Changzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ya Peng</last_name>
    </contact>
    <investigator>
      <last_name>Ya Peng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chongqing Three Gorges Central Hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shengli Chen</last_name>
    </contact>
    <investigator>
      <last_name>Shengli Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xinqiao Hospital of Chongqing</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qingwu Yang</last_name>
    </contact>
    <investigator>
      <last_name>Qingwu Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shengli Oilfield Hospital</name>
      <address>
        <city>Dongying</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zongen Gao</last_name>
    </contact>
    <investigator>
      <last_name>Zongen Gao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan People's Hospital</name>
      <address>
        <city>Guangdong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhian Han</last_name>
    </contact>
    <investigator>
      <last_name>Zhian Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhaohui Ma</last_name>
    </contact>
    <investigator>
      <last_name>Zhaohui Ma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital Of Guizhou Medical University</name>
      <address>
        <city>Guiyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hua Yang</last_name>
    </contact>
    <investigator>
      <last_name>Hua Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Hospital of Jilin University</name>
      <address>
        <city>Jilin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yi Yang</last_name>
    </contact>
    <investigator>
      <last_name>Yi Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liaocheng Third People's Hospital</name>
      <address>
        <city>Liaocheng</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cunfeng Song</last_name>
    </contact>
    <investigator>
      <last_name>Cunfeng Song</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linyi People's Hospital</name>
      <address>
        <city>Linyi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qiyi Zhu</last_name>
    </contact>
    <investigator>
      <last_name>Qiyi Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Luoyang Central Hospital</name>
      <address>
        <city>Luoyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liping Wei</last_name>
    </contact>
    <investigator>
      <last_name>Liping Wei</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing First People's Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tong Li</last_name>
    </contact>
    <investigator>
      <last_name>Tong Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haibin Shi</last_name>
    </contact>
    <investigator>
      <last_name>Haibin Shi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanning Second People's Hospital</name>
      <address>
        <city>Nanning</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tong Li</last_name>
    </contact>
    <investigator>
      <last_name>Tong Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantong University</name>
      <address>
        <city>Nantong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kaifu Ke</last_name>
    </contact>
    <investigator>
      <last_name>Kaifu Ke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianmin Liu</last_name>
    </contact>
    <investigator>
      <last_name>Jianmin Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shenzhen Bao'an District People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huawei Ye</last_name>
    </contact>
    <investigator>
      <last_name>Huawei Ye</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hebei General Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fan Zhang</last_name>
    </contact>
    <investigator>
      <last_name>Fan Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PLA 264 Hospital</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingfeng Zhu</last_name>
    </contact>
    <investigator>
      <last_name>Qingfeng Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dong Kuai</last_name>
    </contact>
    <investigator>
      <last_name>Dong Kuai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Binhai Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wanchao Shi</last_name>
    </contact>
    <investigator>
      <last_name>Wanchao Shi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin TEDA Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zaiyu Guo</last_name>
    </contact>
    <investigator>
      <last_name>Zaiyu Guo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The 101st Hospital of Chinese People's Liberation Army</name>
      <address>
        <city>Wuxi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhonghua Shi</last_name>
    </contact>
    <investigator>
      <last_name>Zhonghua Shi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Subei People's Hospital of Jiangsu Province</name>
      <address>
        <city>Yangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Minghua Lv</last_name>
    </contact>
    <investigator>
      <last_name>Minghua Lv</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhangzhou Municipal Hospital of Fujian Province</name>
      <address>
        <city>Zhangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wenhuo Chen</last_name>
    </contact>
    <investigator>
      <last_name>Wenhuo Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Provincial Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liangfu Zhu</last_name>
    </contact>
    <investigator>
      <last_name>Liangfu Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PLA 148 Hospital</name>
      <address>
        <city>Zibo</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hui Zhang</last_name>
    </contact>
    <investigator>
      <last_name>Hui Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, O'Donnell M, Venketasubramanian N, Barker-Collo S, Lawes CM, Wang W, Shinohara Y, Witt E, Ezzati M, Naghavi M, Murray C; Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014 Jan 18;383(9913):245-54. Review. Erratum in: Lancet. 2014 Jan 18;383(9913):218.</citation>
    <PMID>24449944</PMID>
  </reference>
  <reference>
    <citation>Zhou M, Wang H, Zhu J, Chen W, Wang L, Liu S, Li Y, Wang L, Liu Y, Yin P, Liu J, Yu S, Tan F, Barber RM, Coates MM, Dicker D, Fraser M, González-Medina D, Hamavid H, Hao Y, Hu G, Jiang G, Kan H, Lopez AD, Phillips MR, She J, Vos T, Wan X, Xu G, Yan LL, Yu C, Zhao Y, Zheng Y, Zou X, Naghavi M, Wang Y, Murray CJ, Yang G, Liang X. Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet. 2016 Jan 16;387(10015):251-72. doi: 10.1016/S0140-6736(15)00551-6. Epub 2015 Oct 26.</citation>
    <PMID>26510778</PMID>
  </reference>
  <reference>
    <citation>Yang G, Wang Y, Zeng Y, Gao GF, Liang X, Zhou M, Wan X, Yu S, Jiang Y, Naghavi M, Vos T, Wang H, Lopez AD, Murray CJ. Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2013 Jun 8;381(9882):1987-2015. doi: 10.1016/S0140-6736(13)61097-1.</citation>
    <PMID>23746901</PMID>
  </reference>
  <reference>
    <citation>Liu L, Wang D, Wong KS, Wang Y. Stroke and stroke care in China: huge burden, significant workload, and a national priority. Stroke. 2011 Dec;42(12):3651-4. doi: 10.1161/STROKEAHA.111.635755. Epub 2011 Nov 3. Review.</citation>
    <PMID>22052510</PMID>
  </reference>
  <reference>
    <citation>Lindsberg PJ, Pekkola J, Strbian D, Sairanen T, Mattle HP, Schroth G. Time window for recanalization in basilar artery occlusion: Speculative synthesis. Neurology. 2015 Nov 17;85(20):1806-15. doi: 10.1212/WNL.0000000000002129. Review.</citation>
    <PMID>26574535</PMID>
  </reference>
  <reference>
    <citation>Palaniswami M, Yan B. Mechanical Thrombectomy Is Now the Gold Standard for Acute Ischemic Stroke: Implications for Routine Clinical Practice. Interv Neurol. 2015 Oct;4(1-2):18-29. doi: 10.1159/000438774. Epub 2015 Sep 18. Review.</citation>
    <PMID>26600793</PMID>
  </reference>
  <reference>
    <citation>Powers WJ, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC, Johnston KC, Johnston SC, Khalessi AA, Kidwell CS, Meschia JF, Ovbiagele B, Yavagal DR; American Heart Association Stroke Council. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015 Oct;46(10):3020-35. doi: 10.1161/STR.0000000000000074. Epub 2015 Jun 29.</citation>
    <PMID>26123479</PMID>
  </reference>
  <reference>
    <citation>Chen CJ, Ding D, Starke RM, Mehndiratta P, Crowley RW, Liu KC, Southerland AM, Worrall BB. Endovascular vs medical management of acute ischemic stroke. Neurology. 2015 Dec 1;85(22):1980-90. doi: 10.1212/WNL.0000000000002176. Epub 2015 Nov 4. Review.</citation>
    <PMID>26537058</PMID>
  </reference>
  <reference>
    <citation>Macleod MR, Davis SM, Mitchell PJ, Gerraty RP, Fitt G, Hankey GJ, Stewart-Wynne EG, Rosen D, McNeil JJ, Bladin CF, Chambers BR, Herkes GK, Young D, Donnan GA. Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke. Cerebrovasc Dis. 2005;20(1):12-7. Epub 2005 May 30.</citation>
    <PMID>15925877</PMID>
  </reference>
  <reference>
    <citation>Yeung JT, Matouk CC, Bulsara KR, Sheth KN. Endovascular revascularization for basilar artery occlusion. Interv Neurol. 2015 Jan;3(1):31-40. doi: 10.1159/000368968. Review.</citation>
    <PMID>25999990</PMID>
  </reference>
  <reference>
    <citation>Puñal-Riobóo J, Atienza G, Blanco M. Safety and Efficacy of Mechanical Thrombectomy Using Stent Retrievers in the Endovascular Treatment of Acute Ischaemic Stroke: A Systematic Review. Interv Neurol. 2015 Jul;3(3-4):149-64. doi: 10.1159/000430474. Review.</citation>
    <PMID>26279662</PMID>
  </reference>
  <reference>
    <citation>Akins PT, Amar AP, Pakbaz RS, Fields JD; SWIFT Investigators. Complications of endovascular treatment for acute stroke in the SWIFT trial with solitaire and Merci devices. AJNR Am J Neuroradiol. 2014 Mar;35(3):524-8. doi: 10.3174/ajnr.A3707. Epub 2013 Sep 12.</citation>
    <PMID>24029392</PMID>
  </reference>
  <reference>
    <citation>Hann S, Chalouhi N, Starke R, Gandhe A, Koltz M, Theofanis T, Jabbour P, Gonzalez LF, Rosenwasser R, Tjoumakaris S. Comparison of neurologic and radiographic outcomes with Solitaire versus Merci/Penumbra systems for acute stroke intervention. Biomed Res Int. 2013;2013:715170. doi: 10.1155/2013/715170. Epub 2013 Dec 30.</citation>
    <PMID>24490169</PMID>
  </reference>
  <reference>
    <citation>von Kummer R, Broderick JP, Campbell BC, Demchuk A, Goyal M, Hill MD, Treurniet KM, Majoie CB, Marquering HA, Mazya MV, San Román L, Saver JL, Strbian D, Whiteley W, Hacke W. The Heidelberg Bleeding Classification: Classification of Bleeding Events After Ischemic Stroke and Reperfusion Therapy. Stroke. 2015 Oct;46(10):2981-6. doi: 10.1161/STROKEAHA.115.010049. Epub 2015 Sep 1.</citation>
    <PMID>26330447</PMID>
  </reference>
  <reference>
    <citation>Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G; SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007 Jan 27;369(9558):275-82. Erratum in: Lancet. 2007 Mar 10;369(9564):826.</citation>
    <PMID>17258667</PMID>
  </reference>
  <reference>
    <citation>Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998 Oct 17;352(9136):1245-51.</citation>
    <PMID>9788453</PMID>
  </reference>
  <reference>
    <citation>Puetz V, Sylaja PN, Coutts SB, Hill MD, Dzialowski I, Mueller P, Becker U, Urban G, O'Reilly C, Barber PA, Sharma P, Goyal M, Gahn G, von Kummer R, Demchuk AM. Extent of hypoattenuation on CT angiography source images predicts functional outcome in patients with basilar artery occlusion. Stroke. 2008 Sep;39(9):2485-90. doi: 10.1161/STROKEAHA.107.511162. Epub 2008 Jul 10.</citation>
    <PMID>18617663</PMID>
  </reference>
  <reference>
    <citation>Tomsick T, Broderick J, Carrozella J, Khatri P, Hill M, Palesch Y, Khoury J; Interventional Management of Stroke II Investigators. Revascularization results in the Interventional Management of Stroke II trial. AJNR Am J Neuroradiol. 2008 Mar;29(3):582-7. doi: 10.3174/ajnr.A0843.</citation>
    <PMID>18337393</PMID>
  </reference>
  <reference>
    <citation>Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, Sacks D; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the Society of Interventional Radiology. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke. 2003 Aug;34(8):e109-37. Epub 2003 Jul 17. Erratum in: Stroke. 2003 Nov;34(11):2774.</citation>
    <PMID>12869717</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2016</study_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Basilar Artery Occlusion</keyword>
  <keyword>Ischemic Stroke</keyword>
  <keyword>Mechanical Embolectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
    <mesh_term>Cerebrovascular Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

